Liraglutide: a guide to its use in type 2 diabetes mellitus

September 2010
Drugs & Therapy Perspectives;Sep2010, Vol. 26 Issue 9, p1
Academic Journal
Liraglutide, an analogue of glucagon-like peptide-1, is indicated for the treatment of type 2 diabetes mellitus. In clinical trials, once-daily subcutaneous liraglutide improved glycaemic control as monotherapy or in combination with one or two oral antidiabetic drugs. It also was associated with improvements in pancreatic β-cell function, weight loss and a low risk of hypoglycaemia.


Related Articles

  • Efficacy of secondline therapies added to metformin in T2D.  // Diabetes Digest;2012, Vol. 11 Issue 3, p143 

    The article discusses a study conducted by S. C. Liu, Y. K. Tu, M. N. Chien and colleagues comparing the efficacy of second-line antidiabetes drugs in people with T2D taking metformin.

  • FFAR1 found to be a viable therapeutic target in the treatment of T2D.  // Diabetes Digest;2012, Vol. 11 Issue 3, p144 

    The article discusses research being done on free fatty acid receptor 1 (FFAR1) as a viable target for treatment of type 2 diabetes (T2D). It references the study "TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial,"...

  • Saxagliptin: a guide to its use in type 2 diabetes mellitus.  // Drugs & Therapy Perspectives;Aug2010, Vol. 26 Issue 8, p5 

    Oral saxagliptin, a potent, selective dipeptidyl peptidase-4 inhibitor, is a valuable option to improve glycaemic control in patients with type 2 diabetes mellitus. Saxagliptin as addon therapy to monotherapy with metformin, a sulphonylurea or a thiazolidinedione improves glycaemic control and...

  • TODAY Study: Tackling glycaemic control in adolescents.  // Diabetes Digest;2012, Vol. 11 Issue 3, p139 

    The article discusses a research by Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) group comparing early combined treatment effects with metformin alone on glycaemic control revealing that people with T2D benefit from combination treatment initiated early following diagnosis.

  • Incretin-based therapies for type 2 diabetes. Capaldi, Brenda // Practice Nursing;Oct2012, Vol. 23 Issue 10, p508 

    The article discusses the use of incretin-based therapies for people with type 2 diabetes. The number of people with type 2 diabetes is increasing and controlling blood glucose levels in these patients can be challenging. Incretin-based glucagonlike peptide (GLP)-1 receptor agonists and...

  • Interventions for improving glycemic control in type 2 diabetic patients. Vlachou, Evgenia; Vardaki, Zambia; Govina, Urania; Kavga-Paltoglou, Anna; Kutsopoulou-Sofikiti, Vassiliki; Kelesi-Stavropoulou, Martha // Health Science Journal;2011, Vol. 5 Issue 1, p60 

    Background: Type 2 diabetes mellitus is a progressive disease with deterioration of glycemic control over time. The nursing community, nowadays, is well aware of the increasing frequency and health cost burden of the diabetic complications. Monotherapeutic attempts often fail in the long run. We...

  • End of the Road: Diabetes Care When Insulin May Not Be an Option. Stranges, Paul M.; Tingen, Jeffrey M. // Clinical Diabetes;Spring2014, Vol. 32 Issue 2, p87 

    The article presents a case study of a 53-year old man with uncomplicated type 2 diabetes who requires commercial driver's license (CDL) for his occupation. His diabetes was controlled with increasing doses of metformin and glipizide during the first 4 years after his diagnosis. It mentions that...

  • Intensification of Type 2 Diabetes in Adolescents: Guess What? Exercise Wins! Unger, Jeff // Clinical Diabetes;Fall2012, Vol. 30 Issue 4, p164 

    The article discusses a study conducted for identification and intensification of glycemic control for adolescents with type 2 diabetes. The study gave a fair idea about safety, efficacy and durability of the three protocols (Metformin monotherapy, metformin plus rosiglitazone and metformin plus...

  • Combination drug for adults with type 2 diabetes mellitus.  // Clinical Advisor;Sep2015, Vol. 18 Issue 9, p68 

    No abstract available.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics